Global X Japan Co. Ltd. Acquires 11,034 Shares of Gilead Sciences, Inc. $GILD

Global X Japan Co. Ltd. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5,517.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,234 shares of the biopharmaceutical company’s stock after acquiring an additional 11,034 shares during the period. Global X Japan Co. Ltd.’s holdings in Gilead Sciences were worth $1,247,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in GILD. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at $27,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences in the second quarter valued at $30,000. Finally, Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $125.19 on Wednesday. The company has a fifty day simple moving average of $122.61 and a 200-day simple moving average of $116.40. The firm has a market capitalization of $155.32 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 0.69 and a beta of 0.32. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the company earned $2.02 EPS. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Buying and Selling at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares in the company, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. HSBC raised their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Daiwa Capital Markets lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Finally, Rothschild & Co Redburn boosted their price target on Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $131.54.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.